Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416

B. C. Kuenen, M. Levi, J. C M Meijers, V. W M Van Hinsbergh, J. Berkhof, A. K. Kakkar, K. Hoekman, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

Purpose: An increased incidence of thromboembolic events was observed during treatment with cisplatin-gemcitabine plus SU5416 (CG+SU5416), a tyrosine kinase inhibitor targeting the vascular endothelial growth factor (VEGF) receptor-1 and -2. Nine thromboembolic events occurred in eight of 19 patients. We performed an analysis of parameters of the coagulation cascade and vessel wall activation. Materials and Methods: Markers for thrombin generation and endothelial cell activation were measured in three patients treated with CG+SU5416, two of whom developed a thromboembolic event. The results were compared with measurements in six patients treated with CG alone, and in 17 patients treated with SU5416 alone. Results: During cycles 1 and 2 of treatment with CG+SU5416, a significant cycle-dependent activation of both the coagulation cascade and endothelial cells occurred, whereas platelet counts decreased. Change in platelet number had a significant negative predictive effect on soluble (s)-E-selectin levels. Significant activation of the coagulation cascade only was observed in the patients treated with CG alone, whereas in patients treated with SU5416 alone, significant endothelial cell activation was observed. Conclusion: We hypothesize that endothelial cells deprived of VEGF after exposure to SU5416 became activated and more susceptible to damage during treatment with CG+SU5416, which was aggravated by a transient decrease in platelets, which are, among other things, carriers of VEGF. These results suggests that VEGF, in addition to being a permeability, proliferation, and migration factor, also is a maintenance and protection factor for endothelial cells, and that platelets may have a role in maintaining vascular integrity.

Original languageEnglish (US)
Pages (from-to)2192-2198
Number of pages7
JournalJournal of Clinical Oncology
Volume21
Issue number11
DOIs
StatePublished - Jun 1 2003
Externally publishedYes

Fingerprint

gemcitabine
Angiogenesis Inhibitors
Cisplatin
Blood Platelets
Endothelial Cells
Vascular Endothelial Growth Factor A
Therapeutics
Platelet Count
Vascular Endothelial Growth Factor Receptor-1
Vascular Endothelial Growth Factor Receptor-2
E-Selectin
Semaxinib
Thrombin
Protein-Tyrosine Kinases
Blood Vessels
Permeability

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kuenen, B. C., Levi, M., Meijers, J. C. M., Van Hinsbergh, V. W. M., Berkhof, J., Kakkar, A. K., ... Pinedo, H. M. (2003). Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. Journal of Clinical Oncology, 21(11), 2192-2198. https://doi.org/10.1200/JCO.2003.08.046

Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. / Kuenen, B. C.; Levi, M.; Meijers, J. C M; Van Hinsbergh, V. W M; Berkhof, J.; Kakkar, A. K.; Hoekman, K.; Pinedo, H. M.

In: Journal of Clinical Oncology, Vol. 21, No. 11, 01.06.2003, p. 2192-2198.

Research output: Contribution to journalArticle

Kuenen, BC, Levi, M, Meijers, JCM, Van Hinsbergh, VWM, Berkhof, J, Kakkar, AK, Hoekman, K & Pinedo, HM 2003, 'Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416', Journal of Clinical Oncology, vol. 21, no. 11, pp. 2192-2198. https://doi.org/10.1200/JCO.2003.08.046
Kuenen, B. C. ; Levi, M. ; Meijers, J. C M ; Van Hinsbergh, V. W M ; Berkhof, J. ; Kakkar, A. K. ; Hoekman, K. ; Pinedo, H. M. / Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 11. pp. 2192-2198.
@article{6bfc8049ceae48e9a9887f3e898754ed,
title = "Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416",
abstract = "Purpose: An increased incidence of thromboembolic events was observed during treatment with cisplatin-gemcitabine plus SU5416 (CG+SU5416), a tyrosine kinase inhibitor targeting the vascular endothelial growth factor (VEGF) receptor-1 and -2. Nine thromboembolic events occurred in eight of 19 patients. We performed an analysis of parameters of the coagulation cascade and vessel wall activation. Materials and Methods: Markers for thrombin generation and endothelial cell activation were measured in three patients treated with CG+SU5416, two of whom developed a thromboembolic event. The results were compared with measurements in six patients treated with CG alone, and in 17 patients treated with SU5416 alone. Results: During cycles 1 and 2 of treatment with CG+SU5416, a significant cycle-dependent activation of both the coagulation cascade and endothelial cells occurred, whereas platelet counts decreased. Change in platelet number had a significant negative predictive effect on soluble (s)-E-selectin levels. Significant activation of the coagulation cascade only was observed in the patients treated with CG alone, whereas in patients treated with SU5416 alone, significant endothelial cell activation was observed. Conclusion: We hypothesize that endothelial cells deprived of VEGF after exposure to SU5416 became activated and more susceptible to damage during treatment with CG+SU5416, which was aggravated by a transient decrease in platelets, which are, among other things, carriers of VEGF. These results suggests that VEGF, in addition to being a permeability, proliferation, and migration factor, also is a maintenance and protection factor for endothelial cells, and that platelets may have a role in maintaining vascular integrity.",
author = "Kuenen, {B. C.} and M. Levi and Meijers, {J. C M} and {Van Hinsbergh}, {V. W M} and J. Berkhof and Kakkar, {A. K.} and K. Hoekman and Pinedo, {H. M.}",
year = "2003",
month = "6",
day = "1",
doi = "10.1200/JCO.2003.08.046",
language = "English (US)",
volume = "21",
pages = "2192--2198",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416

AU - Kuenen, B. C.

AU - Levi, M.

AU - Meijers, J. C M

AU - Van Hinsbergh, V. W M

AU - Berkhof, J.

AU - Kakkar, A. K.

AU - Hoekman, K.

AU - Pinedo, H. M.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Purpose: An increased incidence of thromboembolic events was observed during treatment with cisplatin-gemcitabine plus SU5416 (CG+SU5416), a tyrosine kinase inhibitor targeting the vascular endothelial growth factor (VEGF) receptor-1 and -2. Nine thromboembolic events occurred in eight of 19 patients. We performed an analysis of parameters of the coagulation cascade and vessel wall activation. Materials and Methods: Markers for thrombin generation and endothelial cell activation were measured in three patients treated with CG+SU5416, two of whom developed a thromboembolic event. The results were compared with measurements in six patients treated with CG alone, and in 17 patients treated with SU5416 alone. Results: During cycles 1 and 2 of treatment with CG+SU5416, a significant cycle-dependent activation of both the coagulation cascade and endothelial cells occurred, whereas platelet counts decreased. Change in platelet number had a significant negative predictive effect on soluble (s)-E-selectin levels. Significant activation of the coagulation cascade only was observed in the patients treated with CG alone, whereas in patients treated with SU5416 alone, significant endothelial cell activation was observed. Conclusion: We hypothesize that endothelial cells deprived of VEGF after exposure to SU5416 became activated and more susceptible to damage during treatment with CG+SU5416, which was aggravated by a transient decrease in platelets, which are, among other things, carriers of VEGF. These results suggests that VEGF, in addition to being a permeability, proliferation, and migration factor, also is a maintenance and protection factor for endothelial cells, and that platelets may have a role in maintaining vascular integrity.

AB - Purpose: An increased incidence of thromboembolic events was observed during treatment with cisplatin-gemcitabine plus SU5416 (CG+SU5416), a tyrosine kinase inhibitor targeting the vascular endothelial growth factor (VEGF) receptor-1 and -2. Nine thromboembolic events occurred in eight of 19 patients. We performed an analysis of parameters of the coagulation cascade and vessel wall activation. Materials and Methods: Markers for thrombin generation and endothelial cell activation were measured in three patients treated with CG+SU5416, two of whom developed a thromboembolic event. The results were compared with measurements in six patients treated with CG alone, and in 17 patients treated with SU5416 alone. Results: During cycles 1 and 2 of treatment with CG+SU5416, a significant cycle-dependent activation of both the coagulation cascade and endothelial cells occurred, whereas platelet counts decreased. Change in platelet number had a significant negative predictive effect on soluble (s)-E-selectin levels. Significant activation of the coagulation cascade only was observed in the patients treated with CG alone, whereas in patients treated with SU5416 alone, significant endothelial cell activation was observed. Conclusion: We hypothesize that endothelial cells deprived of VEGF after exposure to SU5416 became activated and more susceptible to damage during treatment with CG+SU5416, which was aggravated by a transient decrease in platelets, which are, among other things, carriers of VEGF. These results suggests that VEGF, in addition to being a permeability, proliferation, and migration factor, also is a maintenance and protection factor for endothelial cells, and that platelets may have a role in maintaining vascular integrity.

UR - http://www.scopus.com/inward/record.url?scp=0037530506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037530506&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.08.046

DO - 10.1200/JCO.2003.08.046

M3 - Article

VL - 21

SP - 2192

EP - 2198

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -